| Automated Overnight Closed-Loop Glucose Control in Young Children with Type 1 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 21355719 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Background: We evaluated the effectiveness of automated overnight closed-loop (AOCL) insulin delivery and the influence of timing of initiation on glucose control overnight in young children with type 1 diabetes (T1D). Methods: Eight children with T1D (four boys, four girls) (mean ± SD: 9.4 ± 2.7 years old; body mass index, 18.3 ± 2.3 kg/m(2); duration of diabetes, 3.9 ± 2.5years; total daily insulin dose, 0.7 ± 0.1 U/kg/day; glycosylated hemoglobin, 7.9 ± 0.9%) were studied in a clinical research facility on two separate occasions. Subjects had a meal at 18:00 (77 ± 8 g of carbohydrate [CHO]) and snack at 21:00 (21 ± 6 g of CHO), both accompanied by a prandial insulin bolus. In random order, AOCL was started at 18:00 or 21:00 h and ran until 08:00 h the next day. Subcutaneous continuous glucose monitoring data were fed automatically into the model predictive control algorithm. Calculated subcutaneous insulin infusion rates were sent wirelessly to an insulin pump. Plasma glucose was measured to assess closed-loop performance. Results: No rescue CHOs were administered. Time spent with plasma glucose in the target range from 3.9 to 8.0 mmol/L was 50.7% (29.0%, 72.2%), and it did not differ on the two occasions: median (interquartile range), 42% (18%, 64%) versus 58% (32%, 79%) (P = 0.161). Time when plasma glucose was above 8.0 mmol/L (42% [25%, 82%] vs. 29% [14%, 64%], P = 0.093), time below 3.9 mmol/L (0% [0%, 11%] vs. 8% [0%, 17%], P = 0.500), low blood glucose index (0.1 [0.0, 2.5] vs. 1.7 [0.4, 3.3], P = 0.380), plasma glucose at the start of AOCL (12.5 ± 2.7 vs. 11.6 ± 4.2 mmol/L, P = 0.562), and mean overnight plasma glucose (8.3 ± 2.1 vs. 7.5 ± 2.2 mmol/L, P = 0.246) were also similar. Conclusions: AOCL is feasible in young children with T1D. Comparable results were obtained when closed-loop was initiated at 18:00 or 21:00 h. |
| | |
Authors:
|
Daniela Elleri; Janet M Allen; Marianna Nodale; Malgorzata E Wilinska; Jasdip S Mangat; Anne Mette F Larsen; Carlo L Acerini; David B Dunger; Roman Hovorka |
Related Documents
:
|
21267139 - Office management of diabetes in children part 2: common problems. 11947909 - Hyperhomocyst(e)inemia and chlamydia pneumoniae igg seropositivity in patients with cor... 17982429 - Type 1 diabetes as a relapsing-remitting disease? 8392249 - Immunointervention in type 1 (insulin-dependent) diabetes mellitus. 15372359 - Genetic susceptibility and immunological synapse in type 1 diabetes and thyroid autoimm... 12616989 - Antibodies to advanced glycation end products in children with diabetes mellitus. 21116609 - Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation... 21484579 - Research and development of glucokinase activators for diabetes therapy: theoretical an... 15577349 - Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-28 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-3-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 Metabolic Research Laboratories, Institute of Metabolic Science , Cambridge, United Kingdom . |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Ac...
Next Document: Recovery of ?-Cell Functions with Low-Dose Insulin Therapy: Study in Newly Diagnosed Type 2 Diabetes...